Generation Bio Co. (NASDAQ:GBIO) Given Average Rating of “Hold” by Analysts

Shares of Generation Bio Co. (NASDAQ:GBIO) have earned an average rating of “Hold” from the six research firms that are currently covering the stock, MarketBeat reports. Four equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company. The average 1-year target price among brokerages that have issued a report on the stock in the last year is $8.00.

GBIO has been the subject of a number of recent analyst reports. Wedbush reaffirmed an “outperform” rating and issued a $5.00 price objective on shares of Generation Bio in a research report on Tuesday, May 14th. Needham & Company LLC reaffirmed a “buy” rating and issued a $10.00 price objective on shares of Generation Bio in a research report on Tuesday, May 14th.

Generation Bio Price Performance

GBIO opened at $3.19 on Wednesday. Generation Bio has a fifty-two week low of $0.86 and a fifty-two week high of $5.69. The firm has a market capitalization of $212.23 million, a PE ratio of -1.25 and a beta of 2.84. The company’s 50-day moving average is $2.98 and its 200 day moving average is $2.78.

Generation Bio (NASDAQ:GBIO) last posted its earnings results on Monday, May 13th. The company reported ($1.12) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.76). Generation Bio had a negative return on equity of 82.33% and a negative net margin of 1,696.87%. The business had revenue of $4.06 million during the quarter, compared to analyst estimates of $3.02 million. As a group, analysts expect that Generation Bio will post -1.68 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of GBIO. Price T Rowe Associates Inc. MD grew its position in shares of Generation Bio by 28.2% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 8,878,361 shares of the company’s stock valued at $36,136,000 after acquiring an additional 1,952,187 shares during the period. Baker BROS. Advisors LP bought a new position in shares of Generation Bio during the 1st quarter valued at approximately $1,511,000. Acadian Asset Management LLC lifted its stake in shares of Generation Bio by 113.9% during the 1st quarter. Acadian Asset Management LLC now owns 479,835 shares of the company’s stock valued at $1,952,000 after buying an additional 255,468 shares in the last quarter. Bellevue Group AG lifted its stake in shares of Generation Bio by 6.8% during the 1st quarter. Bellevue Group AG now owns 3,861,575 shares of the company’s stock valued at $15,717,000 after buying an additional 244,495 shares in the last quarter. Finally, Los Angeles Capital Management LLC lifted its stake in shares of Generation Bio by 315.6% during the 4th quarter. Los Angeles Capital Management LLC now owns 275,834 shares of the company’s stock valued at $455,000 after buying an additional 209,462 shares in the last quarter. 95.22% of the stock is owned by institutional investors.

Generation Bio Company Profile

Generation Bio Co develops non-viral genetic medicines for the treatment of rare and prevalent diseases. The company develops cell-targeted lipid nanoparticle (ctLNP) platform, a modular delivery system for nucleic acids to avoid off-target clearance by the liver and spleen that enables ctLNPs to persist in systemic circulation, which allows for highly selective and potent ligand-driven targeting to specific tissues and cell types; and novel immune-quiet DNA (iqDNA) to enable long-lasting high levels of gene expression from non-integrating episomes and avoids innate immune sensors that have long prevented DNA from use in non-viral systems.